Despite these concerns, augmenting the initial phase of viral replication specifically within tumour tissues, either through transient systemic or localized intra-tumoural mTOR inhibitor therapy, could provide the added benefit of reducing cancer cell proliferation and inducing a subsequent increase in viral replication, which upon drug removal could elicit a more potent therapeutic immune response [52]. Here, MTOR is linked to cancer.